For weeks Zoono (ASX:ZNO) shares have surged as people demand its products wanting to protect themselves from the coronavirus, but maybe this wasn’t panic buying after all.

This morning the hand sanitiser maker revealed the test results of its Microbe Shield, a silane quaternary ammonium salt contained in its hand sanitisers, against COVID-19.

Two tests were conducted, one against vaccinia, which is an envelope virus — a virus that contains infected cells that can split off and form viruses in their own right.

The other against feline coronavirus, a globally accepted surrogate for COVID-19.

Both tests confirmed efficacy of 99.99 per cent.

Zoono said the results “demonstrate the ability of the Zoono technology to be part of the solution to prevent and protect against the spread of the COVID-19 virus”.

Managing director Paul Hyslop told Stockhead earlier this month there was one key difference with his company’s products.

“We’re about stopping cross-contamination. Other [solutions] may attack the virus but they won’t protect the surfaces or the skin afterwards — they kill only but we kill and protect,” he said.

Shares spiked over 20 per cent this morning. It is now more than a 20-bagger having traded at just 8c in early October last year.


In other ASX health news today:

Uscom (ASX:UCM) is another company that thinks it can help with the coronavirus situation. It’s a cardiovascular monitoring device maker and, according to Uscom, the majority of coronavirus deaths occurred from cardiovascular pulmonary failure.

In an investor presentation to the ASX, it said it could diagnose cardiovascular disease and guide therapy. The company also noted its device was included in China National Health and Medical Commission Guidelines for coronavirus treatments. Shares rose a more modest 4 per cent this morning.